{
    "clinical_study": {
        "@rank": "33735", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Clinical trial to study the effectiveness of oxaliplatin in treating patients who\n      have locally advanced or metastatic colorectal cancer that has been previously treated."
        }, 
        "brief_title": "Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Provide oxaliplatin for patients with previously treated locally advanced or metastatic\n           colorectal cancer who have exhausted all approved therapies for colorectal cancer.\n\n      OUTLINE: This is a multicenter, Treatment Access Program study.\n\n      Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for\n      up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed for at least 30 days.\n\n      PROJECTED ACCRUAL: Approximately one patient per site per month will be accrued for this\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that\n             is not amenable to surgical resection or other potentially curative therapy\n\n               -  Locally advanced OR\n\n               -  Metastatic disease\n\n          -  Patients who progressed on a non-oxaliplatin-containing (control) arm in\n             Sanofi-Synthelabo second-line regulatory trials OR\n\n          -  Patients who have exhausted all approved therapies for colorectal cancer (including\n             fluorouracil and irinotecan) and have received at least 2 prior independent/different\n             chemotherapy regimens\n\n          -  Documented radiological disease progression after last anticancer treatment\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm3\n\n          -  Platelet count at least 75,000/mm3\n\n        Hepatic:\n\n          -  SGOT or SGPT no greater than 6 times upper limit of normal (ULN)\n\n          -  Bilirubin no greater than 2 mg/dL\n\n          -  Alkaline phosphatase no greater than 5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 6 months after study\n\n          -  Adequate organ function and medically stable\n\n          -  No known concurrent peripheral neuropathy\n\n          -  Absence of deep tendon reflexes as the sole neurologic abnormality is allowed\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 30 days since prior chemotherapy\n\n          -  No prior oxaliplatin-based chemotherapy\n\n          -  No other concurrent investigational chemotherapy agents\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 30 days since prior radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 30 days since prior major surgical procedure or intervention\n\n        Other:\n\n          -  At least 30 days since other prior anticancer therapy\n\n          -  No other concurrent anticancer agents\n\n          -  No concurrent participation in any other investigational studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00040820", 
            "org_study_id": "CDR0000069410", 
            "secondary_id": "RPCI-DS-0130"
        }, 
        "intervention": {
            "intervention_name": "oxaliplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxaliplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer", 
            "adenocarcinoma of the colon", 
            "adenocarcinoma of the rectum"
        ], 
        "lastchanged_date": "March 3, 2011", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/RPCI-DS-0130"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263-0001"
                }, 
                "name": "Roswell Park Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Milind Javle, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040820"
        }, 
        "responsible_party": {
            "name_title": "Miland Javle, MD", 
            "organization": "Roswell Park Cancer Institute"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2011"
    }, 
    "geocoordinates": {
        "Roswell Park Cancer Institute": "42.886 -78.878"
    }
}